Showing 2381-2390 of 2751 results for "".
- Study: Sick Patients Get Cosmetic Surgery to Look Healthierhttps://modernaesthetics.com/news/study-sick-patients-get-cosmetic-surgery-to-look-healthier/2473216/Patients dealing with serious illnesses may want cosmetic procedures to make them look healthier, reports a small new Northwestern Medicine study. The patients believe cosmetic surgery may help them feel better in social situations with their friends, family or when they’re at work. &n
- Cynosure and Jeisys Medical Japan Expand Partnershiphttps://modernaesthetics.com/news/cynosure-and-jeisys-medical-japan-expand-partnership/2473209/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- Laser Surgery Lawsuits May be Less Likely with Physician Operatorshttps://modernaesthetics.com/news/laser-surgery-lawsuits-may-be-less-likely-with-physician-operators/2473208/The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery. Researchers analyzed cases of liability claims due to a cutaneou
- The Beauty Health Company Introduces HydraFacial Syndeo Delivery Systemhttps://modernaesthetics.com/news/the-beauty-health-company-introduces-hydrafacial-syndeo-delivery-system/2473205/The Beauty Health Company is rolling out the HydraFacial Syndeo, a digital device that aims to enhance the consumer and provider experience. “As a category creator, we deliver beauty health experiences every day that re-invent our consumer’s relationship with their ski
- Revance Resubmits BLA for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-resubmits-bla-for-daxibotulinumtoxina/2473204/Revance Therapeutics, Inc. has resubmitted its Biologics License Application (BLA) to FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The submission is in response to the Complete Response Letter (CRL) issued by FDA in October 2021. The
- Endo Launches New Consumer Campaign for Qwohttps://modernaesthetics.com/news/endo-launches-new-consumer-campaign-for-qwo/2473202/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- Lights, Camera, Botox!https://modernaesthetics.com/news/lights-camera-botox/2473185/Allergan Aesthetics is hosting an open casting call seeking people who would like to share their BOTOX Cosmetic Story. Building on the success of the original
- Business News: $511M SPAC Merger Deal for Sunevahttps://modernaesthetics.com/news/business-news-511m-spac-merger-deal-for-suneva/2473182/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- Sculptra Gets New Labelhttps://modernaesthetics.com/news/sculptra-gets-new-label/2473175/A new FDA-approved label for Sculptra® (injectable poly-L-lactic acid (PLLA)) from Galderma includes higher dilution, the addition of immediate use reconstitution, new injection techniques, and the optional addition of lidocaine. Sculptra is the first and only FDA-approved PLLA facial in
- Done Deal: RoundTable Healthcare Partners Completes Sale of Revision Skincare and Goodier Cosmetics to Gryphon Investorshttps://modernaesthetics.com/news/done-deal-roundtable-healthcare-partners-completes-sale-of-revision-skincare-and-goodier-cosmetics-to-gryphon-investors/2473172/RoundTable Healthcare Partners completed the previously announced sale of Revision Skincare and Goodier Cosmetics to Gryphon Investors. Terms of the transaction were not disclosed. Revision Skincare’s portfolio includes Nectifirm, Intellishade, D·E·J